KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
KALA BIO (NASDAQ:KALA) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Closed a $12.5 million private placement financing
- Cash resources of $54.2 million as of June 30, 2024
- Funding expected to last into Q4 2025
- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025
The company is advancing its MSC-S platform technology, focusing on KPI-012 for PCED and exploring potential in other eye diseases. Q2 2024 financial results show a net loss of $9.6 million, or $3.16 per share, compared to $10.4 million, or $4.36 per share, in Q2 2023.
KALA BIO (NASDAQ:KALA) ha riportato i risultati finanziari del secondo trimestre 2024 e fornito un aggiornamento aziendale. I principali punti salienti includono:
- Chiusura di un finanziamento per collocamento privato di 12,5 milioni di dollari
- Risorse di cassa di 54,2 milioni di dollari al 30 giugno 2024
- Finanziamenti previsti fino al quarto trimestre del 2025
- Risultati preliminari del trial di fase 2b CHASE di KPI-012 per PCED attesi in Q1 2025
L'azienda sta sviluppando la sua tecnologia della piattaforma MSC-S, concentrandosi su KPI-012 per PCED ed esplorando opportunità in altre malattie oculari. I risultati finanziari del secondo trimestre 2024 mostrano una perdita netta di 9,6 milioni di dollari, ovvero 3,16 dollari per azione, rispetto ai 10,4 milioni di dollari, o 4,36 dollari per azione, nel secondo trimestre del 2023.
KALA BIO (NASDAQ:KALA) informó los resultados financieros del segundo trimestre de 2024 y proporcionó una actualización corporativa. Los puntos destacados incluyen:
- Cierre de un financiamiento privado de 12,5 millones de dólares
- Recursos en efectivo de 54,2 millones de dólares al 30 de junio de 2024
- Se espera que la financiación dure hasta el cuarto trimestre de 2025
- Datos preliminares del ensayo de fase 2b CHASE de KPI-012 para PCED, esperados en Q1 2025
La empresa está avanzando en su tecnología de plataforma MSC-S, centrándose en KPI-012 para PCED y explorando potencial en otras enfermedades oculares. Los resultados financieros del segundo trimestre de 2024 muestran una pérdida neta de 9,6 millones de dólares, o 3,16 dólares por acción, en comparación con 10,4 millones de dólares, o 4,36 dólares por acción, en el segundo trimestre de 2023.
KALA BIO (NASDAQ:KALA)는 2024년 2분기 재무 결과를 보고하고 기업 업데이트를 제공했습니다. 주요 내용은 다음과 같습니다:
- 1250만 달러의 사모펀드 마감
- 2024년 6월 30일 기준 5420만 달러의 현금 자원
- 자금이 2025년 4분기까지 지속될 것으로 예상됨
- 기대되는 KPI-012의 PCED를 위한 2b상 CHASE 시험의 주요 데이터는 2025년 1분기에 제공될 예정
회사는 MSC-S 플랫폼 기술을 발전시키고 있으며, KPI-012를 PCED에 집중하고 다른 안질환의 가능성을 탐색하고 있습니다. 2024년 2분기 재무 결과는 960만 달러의 순손실을 나타내며, 주당 3.16달러에 해당하고, 이는 2023년 2분기의 1040만 달러(주당 4.36달러)와 비교됩니다.
KALA BIO (NASDAQ:KALA) a publié ses résultats financiers pour le deuxième trimestre 2024 et a fourni une mise à jour de l'entreprise. Les principaux points saillants incluent :
- Clôture d'un placement privé de 12,5 millions de dollars
- Ressources en liquidités de 54,2 millions de dollars au 30 juin 2024
- Financement prévu jusqu'au quatrième trimestre 2025
- Données préliminaires de l'essai de phase 2b CHASE de KPI-012 pour PCED attendues au Q1 2025
L'entreprise fait progresser sa technologie de plateforme MSC-S, en se concentrant sur KPI-012 pour PCED et en explorant des potentiels dans d'autres maladies oculaires. Les résultats financiers du deuxième trimestre 2024 montrent une perte nette de 9,6 millions de dollars, soit 3,16 dollars par action, par rapport à 10,4 millions de dollars, soit 4,36 dollars par action, au deuxième trimestre 2023.
KALA BIO (NASDAQ:KALA) hat die finanziellen Ergebnisse für das zweite Quartal 2024 bekannt gegeben und ein Unternehmensupdate bereitgestellt. Wichtige Highlights sind:
- Abschluss einer Privatplatzierung in Höhe von 12,5 Millionen US-Dollar
- Bargeldmittel von 54,2 Millionen US-Dollar zum 30. Juni 2024
- Finanzierung voraussichtlich bis ins vierte Quartal 2025
- Topline-Daten der Phase 2b CHASE-Studie zu KPI-012 für PCED erwartet in Q1 2025
Das Unternehmen entwickelt seine MSC-S-Plattformtechnologie weiter und konzentriert sich auf KPI-012 für PCED bei gleichzeitiger Erkundung potenzieller Anwendungen bei anderen Augenerkrankungen. Die finanziellen Ergebnisse des zweiten Quartals 2024 zeigen einen Nettoverlust von 9,6 Millionen US-Dollar, oder 3,16 US-Dollar pro Aktie, im Vergleich zu 10,4 Millionen US-Dollar, oder 4,36 US-Dollar pro Aktie, im zweiten Quartal 2023.
- Secured $12.5 million in private placement financing
- Cash resources increased to $54.2 million as of June 30, 2024
- Funding expected to last into Q4 2025
- Phase 2b CHASE trial for KPI-012 progressing with topline data expected in Q1 2025
- Potential market opportunity with estimated 100,000 PCED patients in the U.S.
- Exploring KPI-012 for additional indications like Limbal Stem Cell Deficiency
- Net loss of $9.6 million in Q2 2024
- Increased R&D expenses to $5.3 million in Q2 2024 from $4.3 million in Q2 2023
- Operating loss of $21.5 million for the first half of 2024
Insights
KALA BIO's Q2 2024 results reveal a mixed financial picture. The
R&D expenses increased
KALA's focus on KPI-012 for PCED is promising. The potential market of 100,000 patients in the U.S. with no FDA-approved treatments presents a significant opportunity. The upcoming Phase 2b CHASE trial results in Q1 2025 are critical for KALA's future. If successful, it could accelerate the path to BLA submission.
The exploration of KPI-012 for LSCD and KPI-014 for inherited retinal diseases demonstrates the versatility of their MSC-S platform. This pipeline diversity could mitigate risk if one indication falters. However, investors should note that success in PCED doesn't guarantee efficacy in other indications and further clinical trials will be necessary.
KALA's strategy to target rare and severe eye diseases is astute. The lack of approved treatments for PCED and LSCD presents a blue ocean opportunity. However, the company faces challenges in market education and adoption given the novelty of their MSC-S platform.
The pipeline-in-a-product approach with KPI-012 could be a double-edged sword. While it offers multiple shots on goal, it also spreads resources thin across various indications. KALA's success will hinge on their ability to prioritize indications and allocate resources effectively. The company's focus on becoming a leader in mesenchymal stem cell secretome therapy could differentiate them in the competitive ophthalmology market, but execution will be key.
-- Closed
-- Cash resources of
-- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025 --
ARLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.
"Following the completion of a
Mr. Iwicki continued, “We believe KPI-012 represents an exciting pipeline-in-a-product opportunity to address multiple severe corneal diseases by targeting their underlying causes with a generally well-tolerated and easily administered therapy. Our clinical progress in PCED will support further exploration of KPI-012 in additional indications such as Limbal Stem Cell Deficiency (LSCD) and other corneal diseases. We are also evaluating our second asset, KPI-014, for the treatment of rare, inherited retinal diseases including Retinitis Pigmentosa and Stargardt Disease. We aim to fully realize the potential of our MSC-S platform technology and establish KALA as a leader in the emerging field of mesenchymal stem cell secretome therapy.”
Second Quarter and Recent Business Highlights:
KALA is advancing an innovative pipeline based on its proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA believes the multifactorial mechanism of action of its MSC-S platform technology may enable it to generate product candidates for a range of ocular orphan diseases and is evaluating the potential development of this technology for multiple rare, front- and back-of-the-eye diseases.
KALA’s lead product candidate, KPI-012 contains growth factors, protease inhibitors, matrix proteins and neurotrophic factors to potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases.
KALA is initially developing KPI-012 for the treatment of PCED, a persistent, non-healing corneal defect or wound that is refractory to conventional treatments which, if left untreated, can lead to significant complications, including infection, corneal perforation/scarring and vision loss. PCED has an estimated incidence of approximately 100,000 patients in the U.S., representing a potentially sizeable market opportunity as there are currently no U.S. Food and Drug Administration (FDA)-approved prescription products with a broad indication for all underlying etiologies of PCED.
- KALA continues to enroll patients in the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012 for the treatment of PCED and plans to report topline data in the first quarter of 2025. Contingent on positive results and subject to discussion with regulatory authorities, the Company believes the CHASE Phase 2b trial could potentially serve as the first of two pivotal studies required to support the submission of a Biologics License Application (BLA) to the FDA.
- KALA is also exploring the potential of KPI-012 for additional rare, front-of-the-eye diseases, including LSCD and other corneal diseases. LSCD is characterized by the loss or deficiency of limbal epithelial stem cells, which can result in recurrent epithelial breakdown, neovascularization, conjunctivalization, inflammation and other sequalae that can lead to significant symptomology and a loss of corneal clarity and vision impairment. Like PCED, LSCD represents a potentially substantial market opportunity, with an estimated incidence of 100,000 patients in the U.S.
KPI-014, KALA’s preclinical program to evaluate the utility of its MSC-S platform for inherited retinal degenerative diseases, contains neurotrophic factors, growth factors, anti-inflammatory or immune-modulatory factors and antioxidant inhibitors with the potential to protect and preserve retinal cell function. Secretomes have demonstrated a neuroprotective effect in both in vitro and in vivo models of retinal degeneration. KALA believes KPI-014 could offer a gene-agnostic approach for the treatment of rare inherited retinal diseases and has initiated preclinical studies to evaluate the utility of KPI-014 for conditions such as Retinitis Pigmentosa and Stargardt Disease.
Corporate Updates:
In June 2024, KALA closed a private placement financing, raising aggregate gross proceeds of
Financial Results:
Cash Position: As of June 30, 2024, KALA had cash and cash equivalents of
Financial Results for the Three Months Ended June 30, 2024:
- G&A Expenses: For the quarter ended June 30, 2024, general and administrative (G&A) expenses were
$4.3 million , compared to$5.0 million for the same period in 2023. The decrease was primarily due to a decrease in administrative and professional service fees. - R&D Expenses: For the quarter ended June 30, 2024, research and development (R&D) expenses were
$5.3 million , compared to$4.3 million for the same period in 2023. The increase was primarily due to an increase in KPI-012 development costs and employee-related costs. - (Gain)/Loss on Fair Value Remeasurement of Contingent Consideration: For the quarter ended June 30, 2024, the gain on fair value remeasurement of contingent consideration, in connection with the acquisition of Combangio, was less than
$0.1 million , compared to a loss of$0.4 million for the same period in 2023. The decrease was primarily due to changes in discount rates, changes in the expected timing and probability of payment and the passage of time. - Operating Loss: For the quarter ended June 30, 2024, loss from operations was
$9.6 million , compared to$9.6 million for the same period in 2023. - Net Loss: For the quarter ended June 30, 2024, net loss was
$9.6 million , or$3.16 per share, compared to a net loss of$10.4 million , or$4.36 per share, for the same period in 2023. The weighted average number of shares used to calculate net loss per share was 3.0 million for the quarter ended June 30, 2024 and 2.4 million for the quarter ended June 30, 2023.
Financial Results for the Six Months Ended June 30, 2024:
- G&A Expenses: For the six months ended June 30, 2024, G&A expenses were
$9.7 million , compared to$11.0 million for the same period in 2023. The decrease was primarily due to a decrease in administrative and professional service fees and employee-related costs, partially offset by an increase in stock-based compensation costs. - R&D Expenses: For the six months ended June 30, 2024, R&D expenses were
$11.7 million , compared to$8.3 million for the same period in 2023. The increase was primarily related to an increase in KPI-012 development costs, as we advance the clinical development of KPI-012, an increase in employee-related costs and an increase in other research and development costs. - Gain on Fair Value Remeasurement of Deferred Purchase Consideration: For the six months ended June 30, 2024, there was no gain on fair value remeasurement of deferred purchase consideration due to the final settlement of the liability in March 2023. For the six months ended June 30, 2023, the gain on fair value remeasurement of deferred purchase consideration was
$0.2 million . - Loss on Fair Value Remeasurement of Contingent Consideration: For the six months ended June 30, 2024, the loss on fair value remeasurement of contingent consideration, in connection with the acquisition of Combangio, was
$0.1 million , compared to a loss of$2.2 million for the same period in 2023. The decrease was primarily due to changes in discount rates, changes in the expected timing and probability of payment and the passage of time. - Operating Loss: For the six months ended June 30, 2024, loss from operations was
$21.5 million , compared to a loss of$21.3 million for the same period in 2023. - Net Loss: For the six months ended June 30, 2024, net loss was
$21.4 million , or$7.32 per share, compared to a net loss of$24.9 million , or$11.15 per share, for the same period in 2023. The weighted average number of shares used to calculate net loss per share was 2.9 million for the six months ended June 30, 2024 and 2.2 million for the six months ended June 30, 2023.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements in this press release about KALA’s future expectations, plans and prospects, including but not limited to statements about KALA’s expectations with respect to potential advantages of KPI-012 and its MSC-S platform; the clinical utility of KPI-012 for PCED; anticipated timelines to report topline data for the CHASE Phase 2b clinical trial of KPI-012; KALA’s belief that the Chase Phase 2b trial could serve as the first of two pivotal trials required to support the submission of a BLA to the FDA; KALA’s plans to pursue research and development of KPI-012 and its MSC-S platform for other indications; expectations about the potential benefits and future operation of the CIRM award; KALA’s ability to achieve the specified milestones and obtain the full funding under the CIRM award; the sufficiency of KALA’s existing cash resources for the period anticipated; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: KALA’s ability to comply with the requirements under the CIRM award; uncertainties inherent in the initiation and conduct of preclinical studies and clinical trials; uncertainties regarding availability and timing of data from clinical trials; whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials; whether results of the Phase 1b clinical trial of KPI-012 will be indicative of results for any future clinical trials and studies of KPI-012, including the CHASE Phase 2b clinical trial; whether interim data from a clinical trial will be predictive of the results of the trial; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; KALA’s ability to retain and hire key personnel; KALA’s ability to comply with the covenants under its loan agreement, including the requirement that its common stock continue to be listed on The Nasdaq Stock Market; the sufficiency of cash resources and need for additional financing and other important factors, any of which could cause KALA’s actual results to differ from those contained in the forward-looking statements, discussed in the “Risk Factors” section of KALA’s Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other filings KALA makes with the Securities and Exchange Commission. These forward-looking statements represent KALA’s views as of the date of this press release and should not be relied upon as representing KALA’s views as of any date subsequent to the date hereof. KALA does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Financial Tables:
KALA BIO, Inc. Balance Sheet Data (in thousands) (unaudited) | |||||||
June 30, 2024 | December 31, 2023 | ||||||
Cash and cash equivalents | $ | 54,197 | $ | 50,895 | |||
Total assets | 61,606 | 55,949 | |||||
Working capital (1) | 39,663 | 44,524 | |||||
Current portion of long-term debt | 11,985 | — | |||||
Long-term debt, net of discounts | 22,832 | 34,190 | |||||
Other long-term liabilities | 5,867 | 5,909 | |||||
Total stockholders’ equity | 13,717 | 7,504 |
(1) | The Company defines working capital as current assets less current liabilities. See the Company’s consolidated financial statements for further information regarding its current assets and current liabilities. |
KALA BIO, Inc. Consolidated Statement of Operations (In thousands, except share and per share data) (Unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
Costs and expenses: | |||||||||||||||
General and administrative | $ | 4,317 | $ | 4,962 | $ | 9,739 | $ | 10,992 | |||||||
Research and development | 5,317 | 4,278 | 11,668 | 8,314 | |||||||||||
Gain on fair value remeasurement of deferred purchase consideration | — | — | — | (230 | ) | ||||||||||
(Gain) loss on fair value remeasurement of contingent consideration | (29 | ) | 359 | 129 | 2,206 | ||||||||||
Total costs and expenses | 9,605 | 9,599 | 21,536 | 21,282 | |||||||||||
Loss from operations | (9,605 | ) | (9,599 | ) | (21,536 | ) | (21,282 | ) | |||||||
Other income (expense): | |||||||||||||||
Interest income | 504 | 718 | 1,008 | 1,393 | |||||||||||
Interest expense | (1,458 | ) | (1,413 | ) | (2,913 | ) | (2,887 | ) | |||||||
Grant income | 980 | — | 2,055 | — | |||||||||||
Other expense, net | — | (119 | ) | — | (2,092 | ) | |||||||||
Total other income (expense) | 26 | (814 | ) | 150 | (3,586 | ) | |||||||||
Net loss | $ | (9,579 | ) | $ | (10,413 | ) | $ | (21,386 | ) | $ | (24,868 | ) | |||
Net loss per share attributable to common stockholders—basic and diluted | $ | (3.16 | ) | $ | (4.36 | ) | $ | (7.32 | ) | $ | (11.15 | ) | |||
Weighted average shares outstanding—basic and diluted | 3,030,213 | 2,387,793 | 2,921,712 | 2,229,370 | |||||||||||
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
What were KALA BIO's Q2 2024 financial results?
When is KALA BIO expecting topline data from the Phase 2b CHASE trial for KPI-012?
How much funding did KALA BIO secure in its recent private placement?